These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 3472017)

  • 1. Kinetics of normal hemopoietic stem cells during leukemia growth before and after induction of a complete remission. Studies in a rat model for acute myelocytic leukemia (BNML).
    Martens AC; Hagenbeek A
    Leuk Res; 1987; 11(5):453-9. PubMed ID: 3472017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cryopreservation of autologous marrow grafts in acute leukemia: survival of in vivo clonogenic leukemic cells and normal hemopoietic stem cells.
    Hagenbeek A; Martens AC
    Leukemia; 1989 Jul; 3(7):535-7. PubMed ID: 2659904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response of hematopoiesis to cyclophosphamide follows highly specific patterns in bone marrow and spleen.
    Sefc L; Psenák O; Sýkora V; Sulc K; Necas E
    J Hematother Stem Cell Res; 2003 Feb; 12(1):47-61. PubMed ID: 12662436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterogeneity within the spleen colony-forming cell population in rat bone marrow.
    Martens AC; van Bekkum DW; Hagenbeek A
    Exp Hematol; 1986 Sep; 14(8):714-8. PubMed ID: 3743677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toxicity of ASTA Z 7557 (INN mafosfamide) to normal- and leukemic stem cells: implications for autologous bone marrow transplantation.
    Hagenbeek A; Martens AC
    Invest New Drugs; 1984; 2(2):237-43. PubMed ID: 6381383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamics of leukemic and normal stem cells in leukemic RFM mice.
    Husseini S; Fried W; Knospe WH; Trobaugh FE
    Cancer Res; 1976 May; 36(5):1784-9. PubMed ID: 1268835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics of a monoclonal antibody (RM124) against acute myelocytic leukemia cells.
    Martens AC; Johnson RJ; Kaizer H; Hagenbeek A
    Exp Hematol; 1984 Sep; 12(8):667-71. PubMed ID: 6386506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The proliferative state of normal hemopoietic stem cells during progression of leukemia. Studies in the BN acute myelocytic leukemia (BNML).
    Hagenbeek A; Martens AC
    Leuk Res; 1981; 5(2):141-8. PubMed ID: 6941052
    [No Abstract]   [Full Text] [Related]  

  • 9. Recovery patterns of rat hemopoietic stem cells between pulse doses of 7,12-dimethylbenz(a)anthracene (DMBA) applied in a leukemogenic regimen.
    Fohlmeister I; Hohentanner O; Porr A
    J Cancer Res Clin Oncol; 1986; 111(3):237-42. PubMed ID: 3090051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential sensitivity of adherent CFU-blast, CFU-mix, BFU-E, and CFU-GM to mafosfamide: implications for adjusted dose purging in autologous bone marrow transplantation.
    Carlo-Stella C; Mangoni L; Almici C; Garau D; Craviotto L; Piovani G; Caramatti C; Rizzoli V
    Exp Hematol; 1992 Mar; 20(3):328-33. PubMed ID: 1568448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Role of hematopoietic cells-precursors in the regeneration of hematopoiesis after cytostatic action].
    Bogdashin IV; Buznik DV; Dygaĭ AM; Gol'dberg ED
    Biull Eksp Biol Med; 1992 Jan; 113(1):50-1. PubMed ID: 1391864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of 4-hydroperoxycyclophosphamide on leukemic and normal human myeloid progenitor cells.
    Delforge A; Loos M; Stryckmans P; Socquet M; Debusscher L; Rongé-Collard E
    Leuk Res; 1985; 9(5):583-6. PubMed ID: 3859709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hematopoietic stem cells in the hereditarily anemic Belgrade laboratory (b/b) rat.
    Ivanović Z; Milenković P; Vasiljevska M; Dekić M
    Exp Hematol; 1995 Oct; 23(11):1218-23. PubMed ID: 7556533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The BN acute myelocytic leukemia (BNML) (a rat model for studying human acute myelocytic leukemia (AML)).
    Martens AC; Van Bekkum DW; Hagenbeek A
    Leukemia; 1990 Apr; 4(4):241-57. PubMed ID: 2195239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperthermic purging in vitro of murine leukemia cells (MK-8057): surviving fractions of normal and leukemic stem cells and the long-term survival of mice injected with the post-hyperthermic leukemia cells.
    Iwasawa T; Hirabayashi Y; Kubota N; Inoue T; Kakehi M; Matsui K
    Exp Hematol; 1991 Jun; 19(5):332-7. PubMed ID: 2026185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acetyldinaline: a new oral cytostatic drug with impressive differential activity against leukemic cells and normal stem cells--preclinical studies in a relevant rat model for human acute myelocytic leukemia.
    el-Beltagi HM; Martens AC; Lelieveld P; Haroun EA; Hagenbeek A
    Cancer Res; 1993 Jul; 53(13):3008-14. PubMed ID: 8319208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of cyclophosphamide and of busulfan on spleen colony-forming units and on hematopoietic stroma.
    Fried W; Kedo A; Barone J
    Cancer Res; 1977 Apr; 37(4):1205-9. PubMed ID: 321118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of myleran on murine hemopoiesis. I. Granulocytic cell line specificity of action on progenitor cells.
    Delmonte L
    Cell Tissue Kinet; 1978 Jul; 11(4):347-58. PubMed ID: 308393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological purging of minimal residual disease from peripheral blood stem cell collections of acute myeloblastic leukemia patients: preclinical studies.
    Motta MR; Mangianti S; Rizzi S; Ratta M; Campanini E; Fortuna A; Fogli M; Tura S; Lemoli RM
    Exp Hematol; 1997 Nov; 25(12):1261-9. PubMed ID: 9357970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BCG treatment of residual disease in acute leukemia: studies in a rat model for human acute myelocytic leukemia (BNML).
    Hagenbeek A; Martens AC
    Leuk Res; 1983; 7(4):547-55. PubMed ID: 6578394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.